Advanced search
Publication Cover
Statistics in Biopharmaceutical Research Volume 12, 2020 - Issue 4
Submit an article Journal homepage
412
Views
9
CrossRef citations to date
0
Altmetric
Letter to the Editor

Rejoinder to Letter to the Editor “The Hazards of Period Specific and Weighted Hazard Ratios”

Ray S. LinGenentech/Roche, South San Francisco, CA; Correspondence[email protected]
,
Ji LinSanofi US, Cambridge, MA; ORCID Iconhttp://orcid.org/0000-0001-7206-6111
ORCID Icon,
Satrajit RoychoudhuryPfizer Inc., New York, NY; ORCID Iconhttp://orcid.org/0000-0003-4001-3036
ORCID Icon,
Keaven M. AndersonMerck & Co., Inc., North Wales, PA;
,
Tianle HuSarepta Therapeutics, Cambridge, MA;
,
Bo HuangPfizer Inc., Groton, CT; ORCID Iconhttp://orcid.org/0000-0002-3088-9328
ORCID Icon,
Larry F. LeonCelgene Co., San Diego, CA;
,
Jason J. Z. LiaoMerck & Co., Inc., North Wales, PA;
,
Rong LiuCelgene Co., Summit, NJ;
,
Xiaodong LuoSanofi US, Bridgewater, NJ;
,
Pralay MukhopadhyayAstra Zeneca, Washington, DC;
,
Rui QinJanssen Research & Development, LLC, Raritan, NJ;
,
Kay TatsuokaBristol-Myers Squibb, Lawrenceville, NJ;
,
Xuejing WangEli Lilly and Company, Indianapolis, IN;
,
Yang WangTeclison Ltd., Montclair, NJ;
,
Jian ZhuServier Pharmaceuticals, Boston, MA;
,
Tai-Tsang ChenGSK, Collegeville, PA
,
Renee IaconaAstra Zeneca, Washington, DC;
& Cross-Pharma Non-Proportional Hazards Working Group show all
Pages 520-521 | Received 05 Aug 2020, Accepted 12 Sep 2020, Published online: 28 Oct 2020

Citations (9)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (4)

Yuan-Li Shen, Sirisha Mushti, Flora Mulkey, Thomas Gwise, Xin Wang, Jiaxi Zhou, Xin Gao, Shenghui Tang, Marc R. Theoret, Richard Pazdur & Rajeshwari Sridhara. (2023) Rejoinder to Comments on “Non-Proportional Hazards – An Evaluation of the MaxCombo Test in Cancer Clinical Trials”. Statistics in Biopharmaceutical Research 15:2, pages 315-317.
Read now
Ray S. Lin, Pralay Mukhopadhyay, Satrajit Roychoudhury, Keaven M. Anderson, Tianle Hu, Bo Huang, Larry F. Leon, Jason J. Z. Liao, Ji Lin, Rong Liu, Xiaodong Luo, Yabing Mai, Rui Qin, Kay Tatsuoka, Yang Wang, Jiabu Ye, Jian Zhu, Tai-Tsang Chen & Renee Iacona. (2023) Comment on “Non-Proportional Hazards – an Evaluation of the MaxCombo Test in Cancer Clinical Trials” by the Cross-Pharma Non-Proportional Hazards Working Group. Statistics in Biopharmaceutical Research 15:2, pages 312-314.
Read now
Yuan-Li Shen, Xin Wang, Mushti Sirisha, Flora Mulkey, Jiaxi Zhou, Xin Gao, Lijun Zhang, Thomas Gwise, Shenghui Tang, Marc Theoret, Richard Pazdur & Rajeshwari Sridhara. (2023) Nonproportional Hazards—An Evaluation of the MaxCombo Test in Cancer Clinical Trials. Statistics in Biopharmaceutical Research 15:2, pages 300-309.
Read now
Satrajit Roychoudhury, Keaven M Anderson, Jiabu Ye & Pralay Mukhopadhyay. (2023) Robust Design and Analysis of Clinical Trials With Nonproportional Hazards: A Straw Man Guidance From a Cross-Pharma Working Group. Statistics in Biopharmaceutical Research 15:2, pages 280-294.
Read now

Articles from other publishers (5)

Yi‐Cheng Tai, Weijing Wang & Martin T. Wells. (2023) Two‐sample inference procedures under nonproportional hazards . Pharmaceutical Statistics 22:6, pages 1016-1030.
Crossref
Xiaodong Luo, Yuan Sun & Zhixing Xu. (2022) A MCP‐Mod approach to designing and analyzing survival trials with potential non‐proportional hazards. Pharmaceutical Statistics 21:6, pages 1294-1308.
Crossref
Dominic Magirr & José L Jiménez. (2022) Design and analysis of group-sequential clinical trials based on a modestly weighted log-rank test in anticipation of a delayed separation of survival curves: A practical guidance. Clinical Trials 19:2, pages 201-210.
Crossref
Torben Martinussen. (2022) Causality and the Cox Regression Model. Annual Review of Statistics and Its Application 9:1, pages 249-259.
Crossref
Revathi Ananthakrishnan, Stephanie Green, Alessandro Previtali, Rong Liu, Daniel Li & Michael LaValley. (2021) Critical review of oncology clinical trial design under non-proportional hazards. Critical Reviews in Oncology/Hematology 162, pages 103350.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.